
1st Phorm’s ‘110% Money-Back Guarantee’
Money-back guarantee comes up woefully short of advertised percentage.
Fust et al. v. Gilead Sciences, Inc.
23-at-1244, E.D. Cal.
(Sept. 2023)
Remdesivir
Falsely marketing Remdesivir as safe and effective against COVID-19 without disclosing its limitations and adverse events, including fatalities
Pending
Money-back guarantee comes up woefully short of advertised percentage.
Is it still a guarantee if it has strings attached?
Lawsuits allege “100%” marketing on front label is misleading.
TINA.org reader was charged a lot more than the advertised price. He’s not alone.
TINA.org explores the divide between the marketing and the science.